Please login to the form below

Not currently logged in
Email:
Password:

Yale Cancer Center joins BMS’ II-ON

Becomes the 16th institute to join the network

BMSBristol-Myers Squibb has bolstered the International Immuno-Oncology Network (II-ON) with the addition of the Yale Cancer Center.

Launched in 2012, the II-ON sees the collaboration of industry and academia driving the further enhancement of immuno-oncology research.

Operating under a peer-to-peer approach, the network - which was the first of its kind - has expanded from 10 to 16 sites spanning across North America, Europe, Japan and Australia.

Becoming the 16th organisation to join the network, Roy Herbst, director of the center of immuno-oncology at the Yale Cancer Center, hopes their work can “ultimately help to achieve [the] goal of transforming the way we treat people affected by cancer”.

He added: “The II-ON gives us the chance to work more efficiently and collaboratively with Bristol-Myers Squibb and the other II-ON academic centres to address scientific questions in immuno-oncology.”

Recently, the network has been focusing on generative innovative immuno-oncology science, launching biology-driven trials and applying ‘cutting-edge’ technologies with the goal of translating research findings into clinical trials.

Nils Lonberg, head of oncology biology discovery at Bristol-Myers Squibb, said: “Translational medicine and the understanding of cancer biology are foundational to our oncology R&D programme, which is why we’re invested in furthering the understanding of early I-O Science through the II-ON.

“By adding Yale Cancer Center to the network, we are strengthening our collective ability to address essential scientific questions and advance clinical discovery, which we hope will eventually translate into meaningful outcomes for patients.”

In addition to the II-ON, BMS has invested in several other models of scientific collaboration with academic partners, including the Global Expert Centers Initiative (GECI), the Immuno-Oncology Integrated Community Oncology Network (IO-ICON) and the Oncology Academic Research Group (OAR).

Article by
Gemma Jones

27th February 2018

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics